Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.

MLA

Chen, Kuen-Feng, et al. “Synergistic Interactions between Sorafenib and Bortezomib in Hepatocellular Carcinoma Involve PP2A-Dependent Akt Inactivation.” Journal of Hepatology, vol. 52, no. 1, Jan. 2010, pp. 88–95. EBSCOhost, https://doi.org/10.1016/j.jhep.2009.10.011.

APA

Chen, K.-F., Yu, H.-C., Liu, T.-H., Lee, S.-S., Chen, P.-J., & Cheng, A.-L. (2010). Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Journal of Hepatology, 52(1), 88–95. https://doi.org/10.1016/j.jhep.2009.10.011

Chicago

Chen, Kuen-Feng, Hui-Chuan Yu, Tsung-Hao Liu, Shoei-Sheng Lee, Pei-Jer Chen, and Ann-Lii Cheng. 2010. “Synergistic Interactions between Sorafenib and Bortezomib in Hepatocellular Carcinoma Involve PP2A-Dependent Akt Inactivation.” Journal of Hepatology 52 (1): 88–95. doi:10.1016/j.jhep.2009.10.011.